Cost-effectiveness of continuous erythropoietin receptor activator in anemia

BACKGROUND: Erythropoiesis-stimulating agents (ESAs) are the mainstay of anemia therapy. Continuous erythropoietin receptor activator (CERA) is a highly effective, long-acting ESA developed for once-monthly dosing. A multitude of clinical studies has evaluated the safety and efficiency of this treat...

Descripción completa

Detalles Bibliográficos
Autor principal: Schmid, Holger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4090042/
https://www.ncbi.nlm.nih.gov/pubmed/25050070
http://dx.doi.org/10.2147/CEOR.S46930

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4090042/
https://www.ncbi.nlm.nih.gov/pubmed/25050070
http://dx.doi.org/10.2147/CEOR.S46930

Ejemplares similares